81 related articles for article (PubMed ID: 665130)
1. [Preparation and clinical use of a new factor IX concentrate].
Lopaciuk S; Poszwiński P
Acta Haematol Pol; 1978; 9(2):107-12. PubMed ID: 665130
[TBL] [Abstract][Full Text] [Related]
2. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
5. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
6. Surgical operation in hemophilia B. Use of factor IX concentrate.
Kasper CK
Calif Med; 1970 Jul; 113(1):4-8. PubMed ID: 5520728
[TBL] [Abstract][Full Text] [Related]
7. Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.
Benny AG; Ockelford PA; Johns AS; Woodfield DG; Berry EW
N Z Med J; 1986 Jun; 99(803):408-9. PubMed ID: 3461352
[TBL] [Abstract][Full Text] [Related]
8. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
Sultan Y; Boyeldieu D; Stieltjes N
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
[TBL] [Abstract][Full Text] [Related]
9. The preparation of the factors IX, II, and X concentrate by means of DEAE cellulos and its therapeutic effectiveness.
Uszyński L; Poszwiński P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1975; 102(5):591-4. PubMed ID: 54310
[TBL] [Abstract][Full Text] [Related]
10. Purification of human factor IX by chromatography of a coagulation factor concentrate.
Suomela H
Thromb Haemost; 1976 Feb; 35(1):211-21. PubMed ID: 989188
[TBL] [Abstract][Full Text] [Related]
11. Preparation and properties of a therapeutic factor IX concentrate.
Suomela H; Myllylä G; Raaska E
Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244
[TBL] [Abstract][Full Text] [Related]
12. [A factor IX-concentrate for the treatment of haemophilia B].
Suomela H; Myllylä G
Duodecim; 1971; 87(1):31-8. PubMed ID: 5539580
[No Abstract] [Full Text] [Related]
13. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
[TBL] [Abstract][Full Text] [Related]
14. Serial changes in the coagulation system following clotting factor concentrate infusion.
Preston FE; Winfield DA; Malia RG; Blackburn EK
Thromb Diath Haemorrh; 1975 Nov; 34(2):475-82. PubMed ID: 1198408
[TBL] [Abstract][Full Text] [Related]
15. Treatment of congenital factor VII deficiency with a new concentrate.
Mariani G; Mannucci PM; Mazzucconi MG; Capitanio A
Thromb Haemost; 1978 Jun; 39(3):675-82. PubMed ID: 705696
[TBL] [Abstract][Full Text] [Related]
16. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
[TBL] [Abstract][Full Text] [Related]
17. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hemophilia B with a new clotting-factor concentrate.
Hoag MS; Johnson FF; Robinson JA; Aggeler PM
N Engl J Med; 1969 Mar; 280(11):581-6. PubMed ID: 5764825
[No Abstract] [Full Text] [Related]
19. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
[TBL] [Abstract][Full Text] [Related]
20. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
